Annual report [Section 13 and 15(d), not S-K Item 405]

SEGMENT INFORMATION (Tables)

v3.25.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:

 

 SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES

    2024     2023  
    For the year ended December 31,  
    2024     2023  
             
License and other revenues   $     $ 3,500  
                 
Research and development costs                
Salaries & related costs     15,345       11,373  
Non-cash stock-based compensation     1,561       1,086  
Other research and development costs (a)     17,454       18,632  
Total research and development costs     34,360       31,091  
                 
General and administrative costs                
Salaries & related costs   $ 10,729     $ 6,942  
Non-cash stock-based compensation     5,067       3,682  
Pre-commercial preparation costs     4,818       1,224  
Other general and administrative costs (b)     9,237       7,156  
Total general and administrative costs   $ 29,851     $ 19,004  
                 
Other segment items (c)     (477 )     7,593  
Net loss   $ (63,734 )   $ (54,188 )

 

(a) Other research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and manufacturing facilities, and consultant-related expenses.
(b) Other general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.
(c) Other segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and other income.